Press release
Cataplexy Pipeline Analysis, 2025 by DelveInsight | Avadel, Axome Therapeutics
Cataplexy Pipeline Analysis
According to DelveInsight, over three key companies are actively advancing more than three therapies for the treatment of cataplexy.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.
Request for a detailed cataplexy pipeline analysis report @ https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the cataplexy Pipeline Report:
*
DelveInsight's analysis of the cataplexy pipeline reveals a dynamic landscape, with more than three active companies developing over three investigational therapies across different stages of clinical development.
*
In December 2024, the FDA granted de novo classification and market authorization to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first approved to enhance hand strength and sensation in individuals with chronic cataplexy, with clinical trials showing that 72% of participants experienced improved hand function and sensory perception.
*
Earlier, in May 2024, the FDA approved Abbott's suite of Spinal Cord Stimulation (SCS) systems, including Prodigy, Proclaim Plus, Proclaim XR, and Eterna. These implantable neurostimulators are designed to alleviate chronic pain in the torso, arms, and legs, providing relief for patients with intractable pain conditions.
*
Leading companies such as Avadel, Axome Therapeutics, and others are actively evaluating new therapies to expand treatment options for cataplexy. Notable pipeline candidates in various stages of development include FT218, AXS12, among others.
Cataplexy Overview
Cataplexy is characterized by brief episodes of muscle weakness triggered by strong emotions, particularly positive ones such as laughter or excitement. These sudden attacks, lasting from a few seconds to several minutes, involve partial or complete paralysis of voluntary muscles, while muscles controlling eye movement and breathing remain functional. The condition is associated with the inhibition of serotonergic and noradrenergic neural pathways, which underlies the temporary muscle paralysis seen during cataplectic episodes.
Uncover the latest breakthroughs in cataplexy therapeutics, download our report @ https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cataplexy Pipeline Analysis
The cataplexy pipeline insights report 2025 provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the cataplexy Market.
*
Categorizes cataplexy therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging cataplexy drugs under development based on:
*
Stage of development
*
cataplexy Route of Administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
cataplexy Mechanism of Action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
cataplexy Licensing Agreements
*
Funding and investment activities that support future advancements in the cataplexy market.
Get Full Insights into the cataplexy Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cataplexy Emerging Drugs
*
FT218: Avadel
FT218 is a GABA B receptor agonist originally developed by Flamel Technologies and is now being advanced by Avadel in Phase 3 clinical trials. The study, which started in June 2020 and is expected to finish by June 2022, enrolls around 250 participants (ClinicalTrials.gov ID: NCT04451668).
*
AXS12: Axome Therapeutics
AXS12 (Reboxetine) is a Phase 2 investigational therapy from Axsome Therapeutics for the treatment of cataplexy, acting as an adrenergic reuptake inhibitor.
Currently, around three key companies are actively developing cataplexy therapies, with Avadel leading the field with candidates in the most advanced stage (Phase III).
Cataplexy Pipeline Therapeutic Assessment
Cataplexy Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Cataplexy By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Cataplexy Assessment by Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Cataplexy Assessment by Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
Download the cataplexy Sample Report for Key Insights on the cataplexy Treatment Market and Therapeutics: https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Cataplexy Current Treatment Patterns
4. Cataplexy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cataplexy Late-Stage Products (Phase-III)
7. Cataplexy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cataplexy Discontinued Products
13. Cataplexy Product Profiles
14. Cataplexy Key Companies
15. Cataplexy Key Products
16. Dormant and Discontinued Products
17. Cataplexy Unmet Needs
18. Cataplexy Future Perspectives
19. Cataplexy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the cataplexy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cataplexy-pipeline-analysis-2025-by-delveinsight-avadel-axome-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cataplexy Pipeline Analysis, 2025 by DelveInsight | Avadel, Axome Therapeutics here
News-ID: 4170789 • Views: …
More Releases from ABNewswire
American Plumbing Heating & Cooling Expands Air Conditioning Services Throughout …
American Plumbing Heating & Cooling expands cooling solutions across Southwest Florida with certified technicians, 24/7 emergency service, and transparent pricing for residential and commercial clients.
Sarasota-based HVAC and plumbing specialist American Plumbing Heating & Cooling has announced an expansion of its comprehensive cooling solutions across Southwest Florida. The locally owned company, operating since 2014, continues to address the growing demand for reliable climate control in one of the nation's hottest regions.
With…
Oakland Fence Contractor Patriot Fence Introduces Lifetime Workmanship Guarantee …
Patriot Fence introduces a lifetime artistry warranty for Tennessee fencing projects, combining premium materials like steel posts and thick cedar with comprehensive installation services across Oakland and surrounding communities.
Oakland, TN - A family-owned fence contractor [https://maps.app.goo.gl/r9zPq7b3gvTxNwEK7] is changing how Tennessee residents approach property enhancement and security. Patriot Fence [https://patriotfence901.com/], based in Oakland, has introduced a comprehensive lifetime artistry warranty on all installations, setting a new benchmark for quality assurance in…
Dumpster Rental Harrisonburg Services Expand as Local Company Grows Reach
Staunton-based EZ Dumpster Services expands waste management solutions across Augusta County with diverse container options, demolition support, and junk removal services for residential and commercial customers.
The locally owned waste disposal company based in Staunton, VA, continues building its reputation as a reliable resource for residential and commercial projects throughout the region. With growing demand for efficient waste removal, the company has positioned itself as a practical solution for property owners,…
Oklahoma Roofing Company A&H Roofing & Contracting Expands Service Network Acros …
A&H Roofing & Contracting, LLC expands service coverage across 14 Oklahoma communities while enhancing emergency response capabilities and maintaining local, family-owned values with 26 years of combined roofing expertise.
A&H Roofing & Contracting, LLC has announced significant enhancements to its service capabilities across the Tulsa metropolitan area and surrounding Oklahoma communities. The family-owned business, operating for over 16 years with 26 combined years of expertise, has expanded its coverage to serve…
More Releases for Cataplexy
Cataplexy Market Comprehensive Analysis: Significant Growth Expected Across 7MM …
DelveInsight's comprehensive cataplexy market analysis reveals significant growth potential through 2034, driven by rising prevalence, technological advancements, and promising pipeline therapies. With limited current treatment options and unmet medical needs, the market presents substantial opportunities for pharmaceutical companies developing innovative cataplexy-specific therapies across the 7MM.
Key Findings
*
Market size projection: As per DelveInsight's analysis, the total market size of cataplexy in the 7MM is expected to change significantly during the forecast period…
Cataplexy Pipeline Insight, 2025: Advancing Therapeutics for a Complex Neurologi …
Cataplexy, a sudden and transient loss of muscle tone often triggered by strong emotions, is a debilitating symptom commonly associated with narcolepsy type 1. Current treatments primarily focus on symptom management, but significant unmet needs remain for therapies that offer improved efficacy, safety, and quality of life.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" provides an in-depth analysis of the evolving therapeutic landscape for this rare neurological condition. The pipeline features innovative…
Cataplexy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight …
The cataplexy pipeline constitutes 3+ key companies continuously working towards developing 3+ cataplexy treatment therapies, according to DelveInsight.
DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.
Request for a detailed cataplexy…
Global Non Cataplexy Narcolepsy Drugs Market Analysis By Major Manufacturers and …
Non Cataplexy Narcolepsy Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Non Cataplexy Narcolepsy Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Children (Under 18) and Adult (18 to 50) are the major drivers for the industry.
Global Non…
Cataplexy Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Cataplexy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Cataplexy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cataplexy market size from 2019 to 2032, segmented…
Cataplexy Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Cataplexy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Cataplexy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cataplexy market size from 2019 to 2032, segmented…
